Target intelligence / Profile preview

Clostridioides difficile toxins and surface antigens (C. difficile toxins/antigens)

Target
C. difficile toxins/antigens
Molecular classification
Bacterial toxin, Bacterial surface protein, Antigen, Glucosyltransferase
01

Overview

Clostridioides difficile toxins and associated surface/lysate antigens are the primary virulence factors and structural components of the Gram-positive bacterium C. difficile, which is the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis (Crobach et al., 2016). The major toxins, Toxin A (TcdA) and Toxin B (TcdB), are large glucosyltransferases that target and inactivate Rho-family GTPases within host intestinal epithelial cells, resulting in cytoskeletal disruption, cell death, and a robust inflammatory response (Kuehne et al., 2010). Surface antigens, such as surface layer proteins (SLPs), flagellar proteins (FliC, FliD), and the protease Cwp84, play critical roles in the adhesion and colonization of the bacterium within the host gut (Péchiné et al., 2013). These molecules are significant therapeutic targets; for instance, the monoclonal antibody bezlotoxumab specifically binds and neutralizes TcdB to reduce the recurrence of C. difficile infection (Wilcox et al., 2017). Furthermore, various vaccine candidates utilize toxoids or recombinant fragments of these antigens to elicit protective immunity, aiming to prevent both the initial infection and subsequent relapses (Péchiné et al., 2013).

Other names
C. difficile toxins A and BTcdA and TcdBClostridium difficile antigensC. diff lysate antigensSurface layer proteins (SLPs)C. difficile virulence factors
02

Mechanism of action

Neutralization of Toxin A and Toxin B to prevent intestinal epithelial damage and induction of immune responses against surface antigens to inhibit bacterial colonization.

03

Biological functions

CytotoxicityCell adhesionInflammationBacterial colonizationProtein glucosylationPathogenesis
04

Disease associations

Clostridioides difficile infection (CDI)Pseudomembranous colitisAntibiotic-associated diarrhea
05

Safety considerations

Disease recurrenceHypersensitivity reactionsHeart failure (associated with bezlotoxumab in patients with underlying CHF)Injection site reactions for vaccine candidates
06

Interacting drugs

Bezlotoxumab

4 more in the full profile.

07

Biomarkers

Toxin A/B enzyme immunoassay (EIA)Glutamate dehydrogenase (GDH) antigenC. difficile toxin gene PCR (NAAT)

Beyond the preview

Go deeper on Clostridioides difficile toxins and surface antigens (C. difficile toxins/antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clostridioides difficile toxins and surface antigens (C. difficile toxins/antigens).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call